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S U M M A R Y
Preterm birth is the leading cause of death in newborns and children. Despite advances in perinatology,
immature infants continue to face serious risks such chronic respiratory impairment from
bronchopulmonary dysplasia (BPD). Current treatment options are insufﬁcient and novel approaches
are desperately needed. In recent years stem cells have emerged as potential candidates to treat BPD
with mesenchymal stem/stromal cells (MSCs) being particularly promising. MSCs originate from several
stem cell niches including bone marrow, skin, or adipose, umbilical cord, and placental tissues. Although
the ﬁrst MSCs clinical trials in BPD are ongoing, multiple questions remain open. In this review, we
discuss the question of the optimal cell source (live cells or cell products), route and timing of the
transplantation. Furthermore, we discuss MSCs possible capacities including migration, homing, pro-
angiogenesis, anti-inﬂammatory, and tissue-regenerative potential as well.
 2016 Published by Elsevier Ltd.
EDUCATIONAL AIMS
The reader will come to:
 Understand the deﬁnition of stem cells.
 Understand different sorts and sources of stem cells.
 Understand the basic concept of stem cell therapy.
 Appreciate the use of stem cells as a promising new therapy for the prevention of the BPD.
 Realise that testing in clinical medicine is happening, although essential questions about efﬁcacy and ethics remain to be clariﬁed.
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Paediatric Respiratory ReviewsINTRODUCTION
One of the most complex multifactorial syndromes is preterm
birth and, not surprisingly, the leading cause of death in newborns
and children [1,2]. Despite advances in perinatology, immature* Corresponding author. Maastricht University Medical Center, Department of
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1526-0542/ 2016 Published by Elsevier Ltd.infants continue to face serious risks during pregnancy, parturi-
tion and adaptation after birth. Advances in perinatal care have
reduced mortality but morbidity still represents a major burden
which is evident in very low gestational age infants (< 32 weeks
gestation) [3,4]. The magnitude of this burden to both society and
family is enormous. Besides prematurity related cerebral mor-
bidities including spastic cerebral palsy and behavioral deﬁcits
[5,6], approximately 25% of immature infants are confronted with
long-lasting consequences such as chronic respiratory im-
pairment in the form of bronchopulmonary dysplasia (BPD)
[7]. Changes in clinical management have reduced the incidence
M. Mueller, B.W. Kramer / Paediatric Respiratory Reviews 24 (2017) 54–59 55of BPD signiﬁcantly, with a shift towards extreme low gestational
age newborns developing BPD. Thus nowadays, the pathogenesis
of BPD is as a developmental disorder consisting of immaturity
and impaired alveolar and capillary development leading to
incomplete regeneration of the lung [8].
The basic concept of stem cell administration is the prevention
of BPD. However, BPD is a term which is currently used to describe
the chronic problems of preterm infants that survived up to
36 weeks post menstrual age, [PMA] [9]. In other words BPD is
based on a single time point in the continuum of disease and does
not take into account the babies that have already died because of
lung problems. The time point of 36 weeks PMA is questionable
with respect to its predictive value for the future risk and
retrospective value in omitting newborns that may have already
died of more severe lung disease. The clinical management of BPD
in the perinatal period is focused on gas exchange. However, it is
not the most common problem. The pathogenesis of BPD is driven
by chronic inﬂammation in the airways which may have its origin
antenatally. Further, postnatal triggers such as mechanical
ventilation, sepsis, and oxygen toxicity may sustain and aggravate
the existing pulmonary inﬂammation [10]. Since systemic steroids
modulate inﬂammation in the airways, but have detrimental side
effects, a local approach would seem preferable. For example, the
local application of glucocorticoids has been tested with encour-
aging effects [11].
In very general terms, we have to consider the development of
BPD as an imbalance of chronic injury and incomplete resolution of
inﬂammation coupled with imperfect repair/regeneration. In the
context of a lung developing outside the uterus, it is an
environment of high oxygen exposure, mechanical stress, and
sepsis with a nutritional supply that may be suboptimal. Together,
the chronic inﬂammation may affect both the alveolo- and
vasculo-genesis of the developing lung which forms the basis of
a disease spectrum that we encounter on the ward and in the out-
patient setting.
Although the pathophysiology of the preterm birth syndrome is
complex, survivors share morbidities with a common link. It isFigure 1. MSCs induced protection of the lung Multiple factors contribute to neonatal 
inﬂammation, prematurity, intrauterine growth restriction (IUGR), sepsis, and chorioa
following factors: homing to the injury sight, transdifferentiation of MSCs, production of 
are ongoing, multiple questions remain open: Which MSCs source, at which dose, wheaccepted that inﬂammatory responses explain the common
features of multi-organ injuries in these infants. For example,
the initial inﬂux of neutrophils, followed by increased numbers of
macrophages, represents the characteristic inﬂammatory changes
in BPD [12]. Further, altered growth factor signaling such as the
release of cytokines and disturbance of growth factor signaling is
present. One of the key factors is transforming growth factor (TGF)-
b which induces apoptosis [13]. Other examples are angiogenic
growth factors, such vascular endothelial growth factor (VEGF) and
its receptors, which modulate dysmorphic capillaries and inﬂu-
ence the subsequent development of pulmonary hypertension
[14]. Additional remodeling or early alveolar epithelial dysfunction
promote lung inﬂammation [15]. Although the pathogenesis of
BPD is well deﬁned, current treatment approaches such as
supportive therapies in combination with vitamin A and caffeine
are insufﬁcient and the results often remain unsatisfactory [16].
Consequently, new therapeutics addressing inﬂammatory
responses and promoting lung regeneration are desperately
needed. Mesenchymal stem/stromal cells (MSCs) possess this
potential [17]. They were shown to modulate innate and adaptive
immune responses, to have anti-apoptotic effects, to decrease
inﬂammation, and to enhance tissue repair, mostly through the
release of paracrine factors (Figure 1) [18,19].
STEM CELLS
Stem cells are deﬁned by their properties with respect to their
ability to undergo self-renewal (proliferation) and to give rise to
more differentiated cells (differentiation) [17]. Proliferation means
the cells renew in principle for an indeﬁnite period. Differentiation
implies changing of the cell properties in cells derived from the
stem cells. These cells that are no longer stem cells have different
functional and phenotypic properties than their parent (stem) cell.
The extent of differentiation of cell types in which stem cells can
differentiate is called potency [20]. In contrast, totipotent or
embryonic stem cells are cells that can differentiate in all cell types,
namely into placental and embryonic tissues. Such individual stemlung injury resulting in bronchopulmonary dysplasia (BPD). These factors include
mnionitis. MSCs protective capacity in prevention/reduction of BPD is based on
paracrine factors, and immune modulation. Although ﬁrst MSCs clinical trials in BPD
n, and which route is the optimal one.
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considerations and limitation around these cells. Stem cells that
can give rise to embryonic tissue are called pluripotent stem cells.
Multipotent stem cells can differentiate to adult cell types. The best
known adult stem cell is probably the hematopoietic stem cell.
MESENCHYMAL STEM/STROMAL CELLS
Mesenchymal stromal or stem cells are cells that can give rise to
tissue types such as cartilage, bone marrow and fat tissue. Stem
cells that can differentiate into multipotent MSCs were ﬁrst
described by Friedenstein et al. in 1970 in hematopoietic organs,
mainly bone marrow. The term ‘‘mesenchymal stem cell’’ was ﬁrst
used in 1991 by Caplan [21,22]. In recent years clinical and animal
studies have focused on mesenchymal stem/stromal cells (MSCs)
as a potential cell graft to prevent/repair perinatal acquired injury
[17]. MSCs originate from stem cell niches such as bone marrow
(BM), skin, or adipose umbilical cord, and placental tissues and
therefore are considered somatic stem cells [23]. MSCs must
adhere to plastic when cultured in a tissue culture ﬂask and
express the surface markers CD73, CD90, and CD105 while lacking
expression of CD45, CD34, CD14/CD11b, CD19/CD79a, and HLA-
DR [24] in addition to having potency to differentiate into
osteogenic, chondrogenic, and adipogenic lineages. From a clinical
point of view, MSCs from placental tissue are of special interest.
First, placental tissue provides a broad opportunity to harvest
MSCs prenatally or postnatally without ethical concerns and as an
autologous source. MSCs can be isolated from placental mem-
branes and tissue [25,26], amniotic ﬂuid [27], umbilical cord blood
[28] and umbilical cord connective tissue (Wharton‘s Jelly)
[29,30]. Secondly, the predominant causes of preterm birth, such
as preeclampsia, have no detrimental impact on the quality of
MSCs [31,32]. MSCs are immune-privileged [33]. Finally, MSCs
possess the capacity to adapt to the microenvironment of injured
organs and therefore, having the heterogeneous pathophysiology
of perinatal injuries in mind, MSCs may target multiple organs at
once [17].
The next basic problem is the availability of the cells in
sufﬁcient numbers at speciﬁc time points. The autologous isolation
from cord blood, placenta or Wharton’s Jelly is an appealing option
but raises serious questions [17]. For example, the process must be
performed according to good manufacturing practice which
implies the careful and time consuming assessment of potential
infectious diseases. From a clinical point of view, the more
immature the infant, the higher the risk for BPD. However, the
most immature infant has the smallest volume of cord blood,
smallest placenta and cord size, impacting on the yield of stem
cells. Thus, the following questions need to be addressed:
(1) If the number of autologous stem cells is insufﬁcient, can we
expand the cells in vitro to obtain the needed numbers?
(2) If we expanded the cells in vitro, under which conditions, and in
which time period, should the expansion be completed in order
to meet the window of opportunity?
Notably, the autologous production process is not only prone to
contamination but also potentially compromised by the loss of the
sample which makes the autologous approach rather cumbersome.
MSCS AND BPD
MSCs based therapies are an attractive strategy since the
strategy can potentially replace/restore lost tissue and/or protect/
salvage injured cells. Firstly, clinical MSCs studies addressed
the pro-angiogenic, anti-inﬂammatory, or tissue-regenerativepotential in adults [34]. Animal studies conﬁrmed prophylactic
and therapeutic MSCs’ capacity to ameliorate BPD [35] leading to
piloting clinical trials in neonates [36]. This clinical concept was
tested in Korea with cells isolated from umbilical cord tissue. The
cell populations were expanded in vitro to achieve sufﬁcient cell
numbers which were then given ‘‘off the shelf’’ from unrelated
donors. In the pilot study, two different doses (in 9 preterm infants
at 25 weeks of gestation with a mean birth weight of 790 g) via the
intratracheal administration route were chosen [36]. This strategy
was successful and longer-term follow-up of these pilot patients is
proceding. Larger studies testing the clinical feasibility are
underway. Nevertheless, questions such as the mode of actions,
the desired cell types or products, and the route of transplantation
need to be addressed.
MSCs have been successfully studied in both preclinical and
clinical studies and in several disorders such as cardiovascular,
neurological, haemato-oncological, and auto-inﬂammatory con-
ditions [34]. The approach of cell graft transplantation developed
over the years has led to the ﬁrst basic question: What type of
transplant and application route is appropriate? Basically this
concept includes the direct or peripheral transplantation of whole
cells, conditioned medium (CM), or puriﬁed and deﬁned compo-
nents of CM (extracellular vehicles: EV). For example, both
intratracheal and intravenous administration of BM-MSCs is
protective in murine models of BPD [37,38]. Given that the
protective effects were attributed in part to paracrine immuno-
modulation, both BM-MSCs and CM were successful [38]. Other
cell sources and both short and long term outcomes were tested as
well, showing comparable beneﬁcial results [39]. The question as
to whether whole cells or rather cell products are most suitable for
BPD remains open and several factors need to be considered. The
peripheral approach is based on key properties of MSCs including
delivery of the cells ‘‘homing’’ to the site of injury. Interestingly,
migration and homing are inﬂuenced by multiple factors including
age, passage, and number of cells, culture conditions, and delivery
method [40]. This migration and homing potential without
tumorigenic potential has been described in different disease
[41,42] and in BPD models previously [38,43]. Chemokines with
chemokine receptors CXCR3, CXCR4 and CXCR6 were identiﬁed as
the key players responsible for cell homing [44]. Further, CXCR4
ligands such as stromal cell-derived factor-1a (SDF-1a) promote
MSCs’ migration to the injury site [45]. Apart from migration and
homing, recent studies have focused on cell free approaches such
as EV [46]. Multiple vehicles are present in the extracellular space,
including shedding vesicles, apoptotic bodies and exosomes.
Exosomes (40–100 nm in diameter) are secreted by cells and
may transfer proteins and functional genetic materials (i.e. mRNA
and microRNAs). They are involved in cell-to-cell signaling/
regulation [47]. Although this approach is very promising, it is
still in its infancy. We also have to consider that stem cells
encourage the growth and even supplement (host) cells [48]. Ad-
ditionally, the immunomodulation potential of MSCs may depend
on the bidirectional communication between the injured host cells
and the graft [49]. Together multiple transplantation routes and
graft types have been successfully tested in diverse injury models
including BPD. Regardless of the transplantation route, the basic
mode of action is paracrine immunomodulation [17].
MSCS AND MODE OF ACTION
MSCs response to injury is a crucial advantage over non-cell
based therapies. A vast amount of data has originated from adult
pulmonary diseases or in-vitro studies. Studies have identiﬁed key
factors including cytokines, interleukins, and trophic factors
predominately involved in angiogenesis, hematopoiesis or neuro-
nal and cardiovascular regeneration [50–52]. Classical examples
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possess anti-inﬂammatory capacity [33]. Stanniocalcin-1, hepato-
cyte growth factor (HGF) and vascular endothelial growth factor
(VEGF) promote lung development or oxidative stress resistance
[53–55]. Importantly, MSCs and/or their secretome have effects well
beyond promoting lung regeneration as well as the modulation of
immune responses [38,47]. For example, MSCs inhibit autoreactive
T cell responses and shift the alveolar macrophages from a M1 (pro-
inﬂammatory) to a M2 (protective) phenotype resulting in reduced
pulmonary injury [56]. Besides T-cell modulation [57], MSCs inhibit
B cell proliferation, neutrophils and monocytes function, and NK
toxicity [58–61]. All these paracrine and immunomodulatory
properties are present after both whole cell and cell derived
product transplantation. However, differences in treatment out-
comes were reported. For example, CM seems to be inferior in long-
term effects but equal or superior in short-term effects compared to
whole cell therapy [38,62]. Thus, a direct interaction with injured
cells may potentiate therapeutic efﬁcacy and in the case of CM or CM
products multiple treatments may be appropriate [35,63]. The
concept of MSCs sensing, integrating, and responding to the
surrounding is intriguing as MSCs potential to replace injured cells
is not proven and a matter of constant debate [64–66]. For example,
MSCs improve myocardial infarction without permanent replace-
ment after intravenous application [67]. However, these cells
embolise and cause endothelial damage in the lung as well [67]. In
conclusion, MSCs’ low rate of in vivo engraftment and differentiation
suggest paracrine immunomodulation, but whether factors released
by the MSCs or the cells themselves are the best choice remains an
open question. Especially as whole cell transplantation carries risks
of tumorigenic potential [21,22] this approach needs to be carefully
considered. From a clinical perspective two scenarios are possible:
(1) a malignant transformation of the cell transplant itself and (2) an
immunosuppressive effect of MSCs, which leads to growth of
existing malignant cells in a patient [68]. Notably, the tumourigenic
potential of the stem cell is primarily affected by the manufacturing
process and the cellular source. For example, the risk of
tumourigenic potential is higher for autologous cells due to slower
or absent clearance by the immune system after transplantation
[68]. Although no malignant tumourigenic transformation has been
previously reported, the potential for transformation must be
further explored and monitored in a clinical setting with long
follow-up period, especially as treatments is initiated in immature
infants. Additional studies addressing the long term impact on the
immune system needs to be addressed as well.
SUMMARY
In summary, MSCs represent new potent therapeutic options to
treat multiple disorders associated with preterm birth including
BPD. Given that BPD is a developmental disorder with deregulated
inﬂammatory responses, MSCs primary mode of action is to
modulate innate and adaptive immunity and decrease inﬂamma-
tion while enhancing tissue repair (Figure 1). While autologous
MSCs such as placental tissue are easy available without ethical
concerns, the question of sufﬁcient cell number and availability at
speciﬁc time point remains unanswered. Thus, the concept of cell
products such as conditioned media or puriﬁed and deﬁned
components of condition media (extracellular vehicles) has
emerged recently. The protective paracrine and immunomodulato-
ry properties are present after both whole cell and cell derived
product transplantation but several questions remain unanswered.
Since whole cells may provide a direct interaction with injured cells,
cell derived products may require multiple treatments. However, as
whole cell transplantation carries risks of tumourigenic potential,
this approach needs to be carefully considered. Future basic and
clinical research needs to address following the knowledge gaps:the optimal cell source (autologous versus allogenic), cell type
(whole cells in which status versus cell derived products), cell dose
(single versus multiple), transplantation route (intratracheal versus
peripheral), and ﬁnally the patient population.
DIRECTIONS FOR FUTURE RESEARCH
Carefully designed studies with long term follow-up need to
give the answers to the essential ﬁve questions:
 Which cells have to be given,
 when,
 in which dose,
 to which patients
 via which route?
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EDUCATIONAL ARTICLE
You can receive 1 CME credit by successfully answering
these questions online.
(A) Visit the journal CME site at http://www.prrjournal.com.
(B) Complete the answers online, and receive your ﬁnal score
upon completion of the test.
(C) Should you successfully complete the test, you may
download your accreditation certiﬁcate (subject to an
administrative charge), accredited by the European Board
for Accreditation in Pneumology.
CME MCQ QUESTIONS
1) Bronchopulmonary dysplasia is deﬁned as:
a. 35-37 weeks PMA inclusive
b. 36-37 weeks PMA inclusive
c. 36-38 weeks PMA inclusive
d. Degree of oxygen need/respiratory support at a certain age
e. 37-39 weeks PMA inclusive
2) Which of the following is true regarding stem cells?
a. Ethical dilemmas make their use almost impossible
b. Stem cells are deﬁned by their proliferation and differen-
tiation
c. Stem cells are an academic myth to generate research
funds
d. Stem cells are useless outside the womb
e. Stem cells can only be used on the donor
3) Which of the following is true regarding sources of
mesenchymal stem cells?
a. Mesenchymal stem cells are a commodity, traded in large
quantities and in consistent quality
b. Mesenchymal stem cells can only be harvested from
embryos
c. Mesenchymal stem cells can be isolated from different
tissues
d. Mesenchymal stem cells can be isolated only from the
mother of the baby
e. Mesenchymal stem cells can give rise to embryonic
tissues such as placenta
4) Which difﬁculties may arise when using MSCs from an
autologous source?
a. Insufﬁcient numbers of cells
b. Cells not available at a speciﬁc time point
c. Cells are contaminated
d. Placenta can’t be used because it is embryonic tissue
e. Loss of sample
5) Which of the following properties is not proposed MSCs’
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